We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.5B
AUM Growth
+$439M
Cap. Flow
+$1.2M
Cap. Flow %
0.02%
Top 10 Hldgs %
41.65%
Holding
136
New
22
Increased
21
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
MBX
MBX Biosciences
MBX
+$87.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$46.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.6M
4
AMGN icon
Amgen
AMGN
+$38.4M
5
UNH icon
UnitedHealth
UNH
+$37.9M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$74.9M
2
THC icon
Tenet Healthcare
THC
+$59.2M
3
VRNA
Verona Pharma
VRNA
+$41.4M
4
GERN icon
Geron
GERN
+$40.6M
5
PCVX icon
Vaxcyte
PCVX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
26
DELISTED
Terns Pharmaceuticals
TERN
$63.1M 1.15%
7,562,971
-56,164
-0.7% -$462K
KROS icon
27
Keros Therapeutics
KROS
$197M
$59.2M 1.07%
1,018,734
-250,000
-20% -$12.3M
JANX icon
28
Janux Therapeutics
JANX
$902M
$57.2M 1.04%
1,258,566
-1,721,262
-58% -$74.9M
ELV icon
29
Elevance Health
ELV
$83.3B
$55.2M 1%
106,200
-61,900
-37% -$33.1M
CRNX icon
30
Crinetics Pharmaceuticals
CRNX
$8.87B
$53.7M 0.98%
1,050,055
-230,745
-18% -$11.9M
TMO icon
31
Thermo Fisher Scientific
TMO
$215B
$52.2M 0.95%
84,400
-47,600
-36% -$28.2M
XTNT icon
32
Xtant Medical Holdings
XTNT
$57.7M
$49.4M 0.9%
73,114,592
– –
RNAM
33
DELISTED
Avidity Biosciences
RNAM
$48M 0.87%
1,044,805
+338,330
+48% +$14.7M
REGN icon
34
Regeneron Pharmaceuticals
REGN
$73.1B
$47.5M 0.86%
45,200
+22,400
+98% +$24.9M
EVH icon
35
Evolent Health
EVH
$405M
$47.1M 0.86%
1,665,115
-940,500
-36% -$24.2M
EXAS
36
DELISTED
Exact Sciences
EXAS
$46.3M 0.84%
679,816
+7,400
+1% +$418K
SIBN icon
37
SI-BONE Inc
SIBN
$801M
$46.2M 0.84%
3,305,801
+75,824
+2% +$1.14M
SWTX
38
DELISTED
SpringWorks Therapeutics
SWTX
$44.6M 0.81%
1,390,631
-316,700
-19% -$11.8M
PCVX icon
39
Vaxcyte
PCVX
$7.76B
$44.2M 0.8%
387,000
-408,900
-51% -$36.9M
CMPX icon
40
Compass Therapeutics
CMPX
$360M
$41.1M 0.75%
22,362,850
– –
CYTK icon
41
Cytokinetics
CYTK
$10.9B
$40.5M 0.74%
766,906
-46,000
-6% -$2.56M
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.7B
$37.1M 0.67%
1,925,300
– –
CRVS icon
43
Corvus Pharmaceuticals
CRVS
$1.12B
$36.7M 0.67%
6,943,654
– –
APLS
44
DELISTED
Apellis Pharmaceuticals
APLS
$36.6M 0.67%
1,270,400
-32,400
-2% -$1.2M
XENE icon
45
Xenon Pharmaceuticals
XENE
$6.25B
$35.9M 0.65%
911,420
+49,058
+6% +$1.98M
UHS icon
46
Universal Health Services
UHS
$10.1B
$35.7M 0.65%
+156,000
New +$33.6M
ICLR icon
47
Icon
ICLR
$13.9B
$35.6M 0.65%
123,900
-50,200
-29% -$15.8M
NBIX icon
48
Neurocrine Biosciences
NBIX
$18.2B
$34.8M 0.63%
302,220
-145,980
-33% -$20M
VERA icon
49
Vera Therapeutics
VERA
$2.33B
$29.9M 0.54%
675,872
– –
BIOA
50
BioAge Labs
BIOA
$963M
$29.6M 0.54%
+1,423,470
New +$28.5M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2024 Portfolio in Review

As of Q3 2024, OrbiMed held 136 positions worth $5.5B, up 8.7% from $5.06B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q3 2024 filing shows 22 new, 21 increased, 31 reduced and 18 closed positions. Its largest new stake was MBX Biosciences: 3,812,215 shares worth $99M. The largest sale was Janux Therapeutics, an estimated $74.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

  • OrbiMed's largest Q3 2024 buy was MBX Biosciences: 3,812,215 shares worth $99M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2024, an estimated $42.6M increase.
  • OrbiMed's biggest Q3 2024 reduction was Janux Therapeutics, cutting an estimated $74.9M.
  • OrbiMed fully exited Verona Pharma in Q3 2024, selling an estimated $41.4M.
  • OrbiMed's ten largest holdings make up 42% of its $5.5B portfolio in Q3 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q3 2024.
  • OrbiMed's portfolio value rose 8.7% quarter-over-quarter to $5.5B.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.